Boston Scientific, a manufacturer of medical devices agreed to acquire a majority stake in M.I.Tech, a publicly traded Korean manufacturer and distributor of medical devices, from Synergy Innovation, a microbial technology developer, for $230m. "M.I.Tech is an innovator in non-vascular stent development, with product offerings that complement our existing stent portfolio, including the differentiated AXIOS™ Stent and Electrocautery Enhanced Delivery System and the flexible and conformable Agile™ Esophageal Stent System. We are committed to investing in technologies that advance care for patients around the world and are eager to work more closely with M.I.Tech to expand their international footprint," Art Butcher, Boston Scientific Executive Vice President and Group President, MedSurg and Asia Pacific.